saccharomyces boulardii
What does the research say about saccharomyces boulardii?
9 health outcomes synthesisedResearch on Saccharomyces boulardii spans 9 health outcomes, with the strongest evidence supporting its use in reducing diarrhea — 9 studies consistently report beneficial effects, particularly in clinical populations such as those undergoing H. pylori eradication or radiotherapy. The most commonly studied dose is 500 mg four times daily, though other doses appear across outcomes.
Strongest evidence
Two outcomes have high evidence strength. Reduced Diarrhea (9 studies, all beneficial) shows a moderate effect size, with a typical dose of 500 mg four times daily. Increased Helicobacter pylori Eradication Rate (5 studies, 4 beneficial, 1 neutral) shows a small effect; the evidence is strongest in adults with H. pylori infection.
Mixed or weaker evidence
Several outcomes have moderate evidence but mixed results. Reduced Diarrhea Rate (11 studies, 8 beneficial, 3 neutral) and Improved H. pylori Eradication Rates (8 studies, 5 beneficial, 3 neutral) both show effect sizes ranging from small to large. Reduced Abdominal Pain (6 studies, 5 beneficial, 1 neutral) also has mixed effect sizes. Three outcomes — Reduced Constipation, Reduced Abdominal Distension, and Reduced Stool Frequency — each have only 3 studies, all beneficial, with moderate to large effect sizes, but the evidence base is small. The weakest evidence is for Reduced Duration of Diarrhea (4 studies, very low strength): 3 small trials found benefit, but the only meta-analysis reported a neutral, non-significant mean difference.
Effective dose patterns
Doses vary across outcomes. For diarrhea reduction, the most consistent dose is 500 mg four times daily (high evidence) or 250 mg once to 500 mg twice daily (moderate evidence). For reduced stool frequency in children, 250 mg twice daily was common. Many studies for other outcomes did not report doses, so no clear dose-response relationship can be determined.
Population insights
The vast majority of research is conducted in clinical populations: patients with H. pylori infection, children with acute gastroenteritis, patients undergoing pelvic radiotherapy, and critically ill tube-fed individuals. Only a few studies include healthy adults, so generalizability to non-clinical populations is uncertain. Benefits appear most consistent in those with an underlying gastrointestinal challenge.
Notable caveats
Publication bias is a recurring concern — positive results are more likely to be published, and null-result studies may be underrepresented. Many studies are short (median 14 days), leaving long-term effects unexamined. Several outcomes rely on small numbers of studies (3–4), making conclusions preliminary. The mixed results for some outcomes (e.g., diarrhea rate, H. pylori eradication) suggest that benefit may be context-dependent, influenced by the specific population, treatment regimen, and outcome definition.
Frequently asked
What is Saccharomyces boulardii good for according to research?
Research shows S. boulardii is most consistently beneficial for reducing diarrhea, with 9 high-evidence studies all reporting positive effects. It also shows promise as an adjunct to H. pylori eradication therapy and for reducing abdominal pain, constipation, and abdominal distension in clinical populations, though the evidence is moderate and sometimes mixed.What dose of Saccharomyces boulardii is typically used in studies?
The most commonly studied dose for diarrhea reduction is 500 mg four times daily. For reducing diarrhea rate in children, doses of 250 mg once or twice daily are common. For other outcomes, doses were often not reported, but when mentioned, they range from 250 mg to 1000 mg per day.Who benefits most from Saccharomyces boulardii?
The strongest evidence comes from clinical populations: patients with H. pylori infection undergoing eradication therapy, children with acute gastroenteritis, and patients receiving pelvic radiotherapy or antibiotics. Effects in healthy adults are not well studied, so generalizability is uncertain.Are there caveats or limitations in the research on Saccharomyces boulardii?
Yes. Publication bias is a major concern — most studies show positive results, and null studies may be less likely to be published. Many studies are short (median 14 days), and several outcomes are based on only 3–4 studies. The mixed results for some outcomes suggest benefit may depend on the specific population and treatment context.Does Saccharomyces boulardii help with H. pylori eradication?
Evidence is moderate. Of 8 studies, 5 reported beneficial effects when S. boulardii is added to standard eradication therapy, but 3 found no significant benefit. Effect sizes are mixed, and the treatment duration in studies was typically only 14 days, so long-term eradication rates are not well assessed.Does Saccharomyces boulardii reduce the duration of diarrhea?
The evidence is very low and conflicting. Three small trials reported reduced diarrhea duration, but the only meta-analysis found a non-significant mean difference. More research is needed before conclusions can be drawn.
- High evidenceReduced Diarrhea
- High evidenceIncreased Helicobacter pylori Eradication Rate
- Moderate evidenceReduced Diarrhea Rate
- Moderate evidenceImproved H Pylori Eradication Rates
- Moderate evidenceReduced Abdominal Pain
- Moderate evidenceReduced Stool Frequency
- Moderate evidenceReduced Abdominal Distension
- Moderate evidenceReduced Constipation
- Very low evidenceReduced Duration of Diarrhea
- Reduced Hospitalization Duration